Donate in Memory, Memorial Donation, to our nonprofit scleroderma charity at sclero.org
We are a full-service nonprofit agency with 2,200+ pages in 22 languages!
In Honor of Caregivers, donate to sclero.org, a nonprofit scleroderma charitable foundation
Scleroderma Newsroom
Janey Willis, ISN News GuideHello, I am Janey Willis, ISN News Manager and ISN Asst. Webmaster. David Becker, ISN Assistant News Guide researches our Autoimmune News section. Jeannie McClelland, ISN Assistant News Guide, researches Scleroderma Medical and Media News. Assistant News Guides Lisa Bulman and Judy Tarro post these stories to our Sclero Forums. Stephen Dickson prepares our RSS Newsfeed.
Scleroderma Medical News
Autoimmune News
Media Stories
ISN Website News
Donations & In Memory
New Personal Stories
Autoimmune Medical News by Date
April 2008
Home Intravenous Immunoglobulin Therapy Safe in Patients With Neuroimmunological Disorders. Intravenous (IV) immunoglobulin therapy has a favourable safety profile for patients with neuroimmunological disorders such as Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, myasthaenia gravis, polymyositis, dermatomyositis, and multifocal motor neuropathy. Doctor's Guide Channel. 04/18/08. (Also see: IVIg, Guillain-Barré Syndrome, and Dermatomyositis/Polymyositis )
Low-dose Prednisolone in Rheumatoid Arthritis (RA): Adverse Effects (AE) of Various Disease Modifying Antirheumatic Drugs (DMARD). Low-dose glucocorticoids retard radiological progression of RA and exhibit a differential effect on survival of DMARD and degree of AE due to DMARD. J Rheumatol April 15 2008 (Also See: Rheumatoid Arthritis and Medications: steroids and DMARDS )
Risk of co-existing autoimmune diseases in 3309 index cases with auto-immune thyroid disease (AITD) and their relatives. AITD patients and their parents are at increased risk of co-existing autoimmune diseases; brothers of AITD subjects are particularly likely to have thyroid dysfunction. Kristien Boelaert. Endocrine Abstracts (2008) 15 P385. (Also see: Autoimmunity and Thyroid Disease )
Cardiovascular risk profile of patients with psoriatic arthritis (PsA) compared to controls-the role of inflammation. PsA may be associated with obesity, hypertension, dyslipidaemia and insulin resistance because of the shared inflammatory pathway. L.-S. Tam. Rheumatology Access Online. April 9, 2008. (Also see: Psoriasis, PsA )
Exogenous tumor necrosis factor - alpha induces suppression of autoimmune arthritis. The role of endogenous TNF-alpha in the induction and propagation of arthritis is well established. However, exogenous TNF-alpha can downmodulate the course of AA, displaying an immunoregulatory functional attribute of this cytokine. Arthritis Research & Therapy 2008, 10:R38. April 1, 2008. (Also See: Arthritis and Medications )
Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis (RA). Severe morning stiffness in the early course of the disease has a high impact on RA patients’ decision to withdraw from working life. G. Westhoff. Rheumatology Access Online. April 15, 2008. (Also See: Rheumatoid Arthritis and Disability )
Results of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener's granulomatosis (WG). Intralesional steroid therapy and conservative endoluminal surgery is an effective strategy for treating airway compromise due to active tracheal and bronchial WG, obviating the need for airway bypass or stenting. S. A. R. Nouraei. European Respiratory Review, 2008;17: 30-32. (Also see: Wegener's Granulomatosis )
Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Remission is possible in up to 24% of patients with peripheral PsA. It is significantly more frequent, but not longer, in patients receiving anti-TNF drugs compared with those treated with traditional DMARDs. F. Cantini. Rheumatology Access Online. April 9, 2008. (Also see: Psoriasis and PsA )
Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. The higher use of DMARDs may indicate that smoking weakens the potency of anti-rheumatic drugs and/or is needed to control an otherwise higher disease activity. G. Westhoff. Rheumatology Access Online. April 4, 2008. (Also see: Rheumatoid Arthritis )
Environmental factors linked to development of autoimmune diseases. The research focused on a protein called the aryl hydrocarbon receptor (AhR). The research found that stimulation of AhR by environmental factors could be involved in development of autoimmune disease. NewsMedical.net. 03/30/08. (Also see: Autoimmunity )
More Vitamin D in Childhood Cuts Later Diabetes Risk. The researchers found that children who were given additional vitamin D were about 30 percent less likely to develop type 1 diabetes than children who didn't receive vitamin D supplements. U.S. News & World Report. 03/29/08. (Also see: Diabetes )
Dermatomyositis and Polymyositis Associated with Malignancy: A 21-year Retrospective Study. In patients with tumor-associated myositis, it was more frequently necessary to administer other immunosuppressive drugs along with glucocorticoids. J Rheumatol 2008;35:438-44. (Also see: Dermatomyositis )
Keep on Surfing!
Go to Autoimmune News: March 2008
Contact ISN. We are a full-service nonprofit scleroderma charitable foundation.
Email: isn@sclero.org or
Post in Sclero Forums!
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702
USA
Toll Free Hotline in U.S.
1-800-564-7099
Direct Line
1-952-831-3091 (U.S.)

Donate in Memory to the nonprofit International Scleroderma Network at sclero.org. We will make a custom donation form and link for you, and send thank you's and acknowledgement cards. We list donors and events in our website and newsletter.

Please help raise awareness of scleroderma and related illnesses by mentioning and linking to the nonprofit International Scleroderma Network at sclero.org in conversations, speeches, web sites, and publications.

(We are also known as the Scleroderma from A to Z web site.)
© Copyright 1998-2009 International Scleroderma Network
All Rights Reserved